Almost 10 billion rubles will be invested in the construction of three pharmaceutical enterprises under offset agreements concluded with the Moscow government. This was reported by the press service of the capital’s Department of Investment and Industrial Policy.
According to Vladimir Efimov, the Moscow vice-mayor for economic policy and Land and Property Relations, as part of offset contracts, investors will create three pharmaceutical facilities to localize production in the city.
“The total investment in the creation of production facilities will amount to 9.8 billion rubles. The city will purchase medicines from these plants for a total of 33.5 billion rubles. The creation of the pharmaceutical enterprises will ensure an uninterrupted supply of 116 medicines that Muscovites need,” Vladimir Efimov said.
The official noted that offsets encourage businesses to invest in the creation or modernization of production of goods necessary for Moscow, and they also create new jobs. Entrepreneurs, in turn, can count on stable long-term procurement on behalf of the city.
The first offset agreement in the pharmaceutical industry in Moscow was signed by Biocad in 2017. According to its terms, the investor invests 3 billion rubles in the creation of an enterprise that produces 40 oncological and immunological drugs.
Earlier it became known that the Moscow authorities concluded an offset agreement with the Moscow Endocrine Plant.